Serum proinflammatory cytokine response in patients with advanced liver tumors following selective internal radiation therapy (SIRT) with (90)Yttrium microspheres.

PURPOSE To determine the changes in serum levels of proinflammatory cytokines within 48 h after selective internal radiation treatment (SIRT) in patients with advanced liver cancers. METHODS AND MATERIALS Twenty-eight patients with advanced liver cancers who underwent SIRT were recruited into the study. Serum levels of interleukin (IL)-1beta, IL-6, IL-8, IL-10, IL-12, tumor necrosis factor-alpha, and interferon-gamma were determined prior to and 3, 6, 12, 24, and 48 h after SIRT. Their changes were correlated to adverse reactions following treatment as assessed by constitutional symptom scores, and routine blood and liver function tests at 24 and 48 h post-SIRT and falls in serum carcinoembryonic antigen (CEA) level 1 month post-SIRT. RESULTS Serum IL-6 levels were significantly increased at 24 (p < or = 0.05) and 48 h (p < or = 0.01) post-SIRT. In contrast, there was no significant change in the serum levels of other cytokines studied. The increase in serum IL-6 at 24 h post-SIRT was significantly correlated with the changes in serum alanine transferase (p < or = 0.05) and C-reactive protein (p < or = 0.001) levels and total leukocyte counts (p < or = 0.001) at both 24 and 48 h post-SIRT. Changes in serum IL-6 level were also significantly correlated to the rise of serum aspartate transaminase levels at 48 h post-SIRT (p < or = 0.001), but not with the scores of constitutional symptoms or the changes of serum CEA at 1 month post-SIRT. CONCLUSION Absence of significant changes in most of proinflammatory cytokines studied confirmed that SIRT is a reasonably safe and well-tolerated treatment with minimal side-effect from the point of view of cytokine-related inflammation. The correlation of serum IL-6 changes with several liver enzymes and C-reactive protein but not with clinical symptom scores or serum CEA levels suggests that the rise in IL-6 levels in the first 48 h following SIRT most likely reflect normal liver cell damage rather than tumor cell damage.

[1]  J. Abrams,et al.  Role of interleukin 6 (IL-6) in protection from lethal irradiation and in endocrine responses to IL-1 and tumor necrosis factor , 1992, The Journal of experimental medicine.

[2]  D. Khayat,et al.  Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy? , 1999, Melanoma research.

[3]  G. Catalano,et al.  Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. , 1998, Oncology reports.

[4]  T. Nose,et al.  Effect of radiotherapy on serum level of interleukin 6 in patients with cervical carcinoma. , 1996, Anticancer research.

[5]  T. Hirano,et al.  The in vivo Anti‐tumor Effect of Human Recombinant Interleukin‐6 , 1990, Japanese journal of cancer research : Gann.

[6]  M. Pirovano,et al.  Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies. , 1996, European journal of cancer.

[7]  M. Weil,et al.  Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  U. Stenram,et al.  Resection of Colorectal Liver Metastases: 25-Year Experience , 1998, World Journal of Surgery.

[9]  B. Barton.  IL-6: insights into novel biological activities. , 1997, Clinical immunology and immunopathology.

[10]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[11]  V. Sondak,et al.  Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. , 1996, Journal of the National Cancer Institute.

[12]  C. Miki,et al.  Serum interleukin‐6 level reflects the tumor proliferative activity in patients with colorectal carcinoma , 1999, Cancer.

[13]  W. Lau,et al.  Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. , 1995, International journal of radiation oncology, biology, physics.

[14]  J. Redpath,et al.  High and low dose rate irradiation have opposing effects on cytokine gene expression in human glioblastoma cell lines. , 1997, European journal of cancer.

[15]  G. Poston,et al.  The aetiology and management of hepatic metastases. , 1997, The Australian and New Zealand journal of surgery.

[16]  M. Burton,et al.  Adjuvant internal radiation therapy in a model of colorectal cancer-derived hepatic metastases. , 1995, British Journal of Cancer.

[17]  M. Chen,et al.  Interleukin‐10 production by human carcinoma cell lines and its relationship to interleukin‐6 expression , 1993, International journal of cancer.

[18]  R. Cannan,et al.  Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. , 2001, Hepato-gastroenterology.

[19]  M. W. Flye,et al.  Endotoxin stimulates interleukin-6 production by human Kupffer cells. , 1992, Circulatory shock.

[20]  A. Harris,et al.  Cytokine networks in solid human tumors: regulation of angiogenesis , 1994, Journal of leukocyte biology.

[21]  M. Anscher,et al.  Normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGFβ , 1995 .

[22]  B. Petrini,et al.  Monocyte release and plasma levels of interleukin-6 in patients irradiated for cancer. , 1992, In vivo.

[23]  J. Lacki,et al.  Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer. , 1996, Neoplasma.

[24]  D. Hallahan,et al.  The role of cytokines in radiation oncology. , 1993, Important advances in oncology.

[25]  T. Hirano,et al.  Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation. , 1989, Clinical immunology and immunopathology.

[26]  A. Ballestrero,et al.  The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer , 1999, Cancer Immunology, Immunotherapy.

[27]  H. Yamazaki,et al.  Serum interleukin 6 as a predicator of the therapeutic effect and adverse reactions after transcatheter arterial embolization. , 1995, Cytokine.

[28]  F. Uckun,et al.  In vivo radiosensitizing effects of recombinant interleukin 6 on radiation resistant BCL-1 B-lineage leukemia cells in a murine syngeneic bone marrow transplant model system. , 1995, Leukemia & lymphoma.

[29]  Shohachi Suzuki,et al.  Resection of Liver Metastases of Colorectal Carcinoma , 1997, World Journal of Surgery.

[30]  A. Li,et al.  Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. , 1998, International journal of radiation oncology, biology, physics.

[31]  Y. Fong,et al.  Surgical treatment of colorectal metastases to the liver , 1995, CA: a cancer journal for clinicians.

[32]  M. Ghiani,et al.  Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. , 1998, Critical reviews in oncogenesis.

[33]  H. Bleiberg.  Colorectal cancer: the challenge. , 1996, European journal of cancer.

[34]  D. Kelleher,et al.  Selective internal radiation (SIR) therapy for treatment of liver metastases: Measurement of response rate , 1989, Journal of surgical oncology.

[35]  A. Li,et al.  Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. , 1994, British Journal of Cancer.

[36]  J. Blay,et al.  The host-tumor immune conflict: from immunosuppression to resistance and destruction. , 1997, Immunology today.

[37]  G. van Hazel,et al.  Regression of liver metastases following treatment with yttrium-90 microspheres. , 2010, The Australian and New Zealand journal of surgery.

[38]  W. Ensminger,et al.  Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  S. Akira,et al.  Biological and clinical aspects of interleukin 6. , 1990, Immunology today.

[40]  J. Lacki,et al.  Prognostic value of serial serum interleukin-6 level estimation in patients with lung cancer: a preliminary report. , 1997, The Yale journal of biology and medicine.

[41]  I. Francis,et al.  Hepatic parenchymal changes after intraarterial Y-90 therapy: CT findings. , 1993, Radiology.

[42]  R. Syljuåsen,et al.  Modification of tumor microenvironment by cytokine gene transfer. , 1995, Acta oncologica.